Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue.
Modus Therapeutics Holding AB is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.
